Early Stage Triple-Negative Breast Carcinoma Clinical Trials

10 clinical trials for Early Stage Triple-Negative Breast Carcinoma across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab — RECRUITING · PHASE3
• Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer — RECRUITING · PHASE2
• Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial — RECRUITING · PHASE2
• Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform — RECRUITING
• Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer — RECRUITING · PHASE1
• Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer — RECRUITING · PHASE3
• TNBC Gut Microbiota During Neoadjuvant Treatment — WITHDRAWN · NA
• Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer — NOT_YET_RECRUITING · PHASE2
• Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy — NOT_YET_RECRUITING · PHASE3
• Implantable Microdevice for TNBC - Pilot Study — WITHDRAWN · PHASE1

Refine this search